Onchocerciasis (River Blindness) – Drugs In Development, 2024
Powered by
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Onchocerciasis (River Blindness) – Drugs In Development, 2024 report and make more profitable business decisions.
Onchocerciasis, or river blindness, is a neglected tropical disease (NTD) caused by the parasitic worm Onchocerca volvulus. It is transmitted through repeated bites by blackflies of the genus Simulium. The disease is called river blindness because the blackfly that transmits the infection lives and breeds near fast flowing streams and rivers. The infection can result in visual impairment and sometimes blindness. Also, onchocerciasis can cause skin disease, itching, rashes, or nodules under the skin.
The Onchocerciasis (River Blindness) drugs in development market research report provide comprehensive information on the therapeutics under development for Onchocerciasis (River Blindness), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Onchocerciasis (River Blindness) and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
Quick View – Onchocerciasis (River Blindness) | Key Targets |
|
|
Key Mechanisms of Action |
|
||
Key Routes of Administration |
|
||
Key Molecule Types |
|
||
Major Companies |
|
Scope
- Therapeutics in Development: Covering 9 molecules, with 7 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Onchocerciasis (River Blindness) therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Onchocerciasis (River Blindness) pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Onchocerciasis (River Blindness) treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Bayer AGBristol-Myers Squibb Co
Drugs for Neglected Diseases initiative
Helix Biogen Institute
Lyndra Therapeutics Inc.
Medicines Development for Global Health Ltd
Pai Life Sciences Inc
University of Washington